Thermostable Vaccines

Thermostable Vaccines and Thermostable Biologics Market by Type of Molecule (Vaccines and Proteins), Target Indications (Covid-19, Diabetes, Enteric Hyperoxaluria, Norovirus Infection and Rotavirus Infection), Type of Therapy, Key Players, and Key Geographical Regions (North America, Europe and Asia Pacific and Rest of the World): Industry Trends and Global Forecasts, 2021-2035

  • Lowest Price Guaranteed From USD 5,899

  • Published
    January 2022

  • Pages
    209

  • View Count
    3982

  • Buy Now

Example Insights

Thermostable-Vaccines-and-Biologics-Context-thumb Thermostable-Vaccines-and-Biologics-Pipeline-thumb Thermostable-Vaccines-and-Biologics-Landscape-thumb
Thermostable-Vaccines-and-Biologics-products-thumb Thermostable-Vaccines-and-Biologics-diseases-thumb Thermostable-Vaccines-and-Biologics-Collaborations-thumb
Thermostable-Vaccines-and-Biologics-Investment-thumb Thermostable-Vaccines-and-Biologics-Scenarios-thumb Thermostable-Vaccines-and-Biologics-regions-thumb

Overview

According to experts, the global vaccines market is anticipated to generate revenues worth USD 100 billion by 2025. Data presented by the WHO indicates that the current global vaccination coverage is nearly 85% this is believed to prevent close to three million deaths from diseases, such as diphtheria, tetanus, whooping cough and measles. However, it has been reported that 25% of vaccines are damaged due to cold chain malfunction (improper distribution and shipping). In some countries, about 80% of the drugs are estimated to lose their potency due to inadequate temperature control during their cold chain transportation. For some vaccines, even the slightest variations in temperature / storage conditions can adversely alter product integrity and / or viability. Over time, technological advancements in the methods of biologics development and manufacturing have prompted the developers to explore the potential of thermostable vaccines and thermostable biologics. Thermostable vaccines can be stored at room temperature for prolonged period of time, thereby eliminating the need for cold chain requirements in storage and transportation. This enables reduction in costs incurred during storage and transportation and, subsequently, the overall costs involved in mass immunization projects. In addition, it allows the suppliers to deliver the products in safe and convenient manner even to far-flung destinations.

At present, several biopharmaceutical companies and clinical research institutes are engaged in the development of thermostable vaccines and thermostable biologics, taking into consideration the rising global population, growing demand for vaccines and specific requirements of large-scale immunization initiatives. Moreover, significant efforts are being put into the development of technologies / devices, which enables transition of conventional vaccines to thermostable vaccines. The market has witnessed substantial partnership activity over the last few years. The activity in this segment of the industry has also attracted the attention of both private and public sector investors / investment funds, which have extended financial support to the initiatives of capable developer companies. Driven by the substantial progress in research in this domain, encouraging clinical trial results, and ongoing technological advancement, the thermostable vaccines and thermostable biologics market is anticipated to grow at a commendable pace in the mid to long-term.

Scope of the Report

The "Thermostable Vaccines and Biologics Market: Distribution by Type of Molecule (Vaccines and Proteins), Target Indications (Covid-19, Diabetes, Enteric Hyperoxaluria, Norovirus Infection and Rotavirus Infection), Type of Therapy, Key Players, and Key Geographical Regions (North America, Europe and Asia Pacific and Rest of the World): Industry Trends and Global Forecasts, 2021-2035" report features an extensive study of the current market landscape and future opportunity for the players involved in the development of thermostable vaccines and biologics for the treatment of a variety of disease conditions. The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different geographies. Amongst other elements, the report includes:

  • An overview of thermostable vaccines and biologics market, featuring a detailed analysis of pipeline molecules, based on several relevant parameters, such as type of molecule, type of formulation, type of manufacturing technology, trial phase (clinical, preclinical and discovery), route of administration, type of storage conditions, type of disease indication (Covid-19, diabetes and others), and target therapeutic area (infectious diseases, metabolic disorders, and others). It also includes information on the completed, ongoing and planned clinical trials for thermostable vaccines and biologics, sponsored by various industry players. It also provides insights on developer landscape along with the analysis based on several parameters, including year of establishment, company size, location of headquarters.
  • An insightful competitiveness analysis of thermostable vaccines and biologics developers, taking into consideration the supplier strength (based on expertise of the manufacturer), product portfolio strength, portfolio diversity, and number of area(s) of application.
  • A detailed analysis of close to 150 peer-review, scientific articles related to research on thermostable vaccines and biologics, such as year of publication, type of publication focus area (therapeutic area), impact factor, most popular author and most popular journals.
  • An analysis of the partnerships that have been inked by various stakeholders engaged in the development of thermostable vaccines and biologics, during the period 2015-2021, covering product development agreements, research and development agreements, licensing agreements, clinical trial agreement, licensing and manufacturing agreement, product development and commercialization manufacturing agreements, joint venture, product development and commercialization, acquisition and other types of partnership deals. 
  • An analysis of the investments made at various stages of development of the companies engaged in this field, covering instances of debt financing, equity investments, Secondary offerings, seed funding, award/grant funding, post-IPO Debt, post-IPO Equity, private equity and other types of funding deals. 
  • Tabulated profiles of the key players providing thermostable vaccines and biologics. Each profile includes an overview of the company, thermostable product portfolio, recent developments, and an informed future outlook.

One of the key objectives of the report was to estimate the future growth potential of thermostable vaccines and biologics market, over the coming decade. Based on multiple parameters, such as target patient population, likely adoption rates and expected pricing, we have provided informed estimates on the financial evolution of the market for the period 2021-2035. For this purpose, we have segmented the future opportunity across the following market segments: Type of Molecule (Vaccines and Proteins), Target Indications (Covid-19, Diabetes, Enteric Hyperoxaluria, Norovirus Infection and Rotavirus Infection), Type of Therapy, Key Players, and Key Geographical Regions (North America, Europe and Asia Pacific and Rest of the World). To account for uncertainties and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the anticipated industry’s growth.

Key Questions Answered

  • Who are the leading players engaged in the development of thermostable vaccines and biologics?
  • Which are the key clinical conditions that can be treated by thermostable vaccines and biologics?
  • What is the trend of investment in this industry?
  • Which partnership models are commonly adopted by stakeholders engaged in the development of thermostable vaccines and biologics domain?
  • Which factors are likely to influence the evolution of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the thermostable vaccines and biologics market and its likely evolution in the short to-mid to long term.

Chapter 3 provides a general introduction to thermostable vaccines and biologics. In addition, we have briefly described the classification of vaccines based on type of active ingredient, limitations of conventional vaccines, thermostability of marketed vaccines, common routes of administration for thermostable vaccines. The chapter also discusses value propositions of thermostable vaccines. 

Chapter 4 presents a detailed assessment of the current market landscape of thermostable vaccines and biologics based therapeutics, along with information on type of biologics (vaccines and proteins), type of indication and therapeutic areas (Covid-19, diabetes and others), storage conditions, type of manufacturing technologies, phase of development (clinical, preclinical, discovery), route of administration, type of formulation. In addition, it provides an overview of the thermostable vaccines-based therapeutics developer landscape, highlighting the players that are active in this domain. It includes information on their year of establishment, company size (in terms of number of employees) and location of their respective headquarters. Further, we have presented a logo landscape, highlighting the distribution of the drug developers based on company size and location of headquarters. 

Chapter 5 includes profiles of the key players engaged in the development of thermostable vaccines and biologics (shortlisted based on strength of product portfolio). Each profile features a brief overview of the company, details on product portfolio, recent developments, and an informed future outlook.

Chapter 6 is an insightful three-dimensional bubble chart representation, highlighting the competitive analysis of thermostable vaccines and biologics manufacturers, taking into consideration the supplier strength (based on expertise of the manufacturer), product portfolio strength, and portfolio diversity.

Chapter 7 features a detailed analysis of publications related to thermostable vaccines and biologics, based on year of publication, type of publication, and focus area, while highlighting the most popular authors journals.

Chapter 8 features a detailed analysis of the partnerships and collaborations that have been inked in this domain since 2015, covering product development agreements, research and development agreements, licensing agreements, clinical trial agreements, licensing and manufacturing agreements, product development and commercialization manufacturing agreements, joint venture, product development and commercialization, acquisition and other relevant types of deals.

Chapter 9 provides an analysis of the key investments made since 2015 at various stages of development of companies engaged in this domain, based on the year of investment, number of funding instances, amount invested and type of funding, highlighting most active players (in terms of number of funding instances and amount raised) and most active investors (in terms of number of funding instances). 

Chapter 10 features an elaborate discussion on the future market potential of thermostable vaccines and biologics. The chapter provides insights on the likely distribution of the current and forecasted opportunity across type of molecule, type of indication, therapeutic area, key players and geographical regions (North America, Europe and Asia-Pacific). 

Chapter 11 is a summary of the overall report, wherein we have mentioned all the key facts and figures described in the previous chapters. 

Chapter 12 is a collection of interview transcript(s) of discussions held with representatives of renowned organizations engaged in the thermostable vaccines and biologics domain

Chapter 13 is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Chapter 14 is an appendix, which provides a list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered Research Methodology
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Vaccines and Biologics
3.3. Classification of Vaccines Based on Type of Active Ingredient
3.4. Limitations of Conventional Vaccines
3.5. Thermostable Vaccines and Biologics
3.5.1. Thermostability of Marketed Vaccines
3.5.2. Common Routes of Administration for Thermostable Vaccines
3.5.2.1. Oral Route
3.5.2.2. Intranasal Route
3.5.2.3. Intradermal Route
3.5.2.4. Inhalation Route
3.5.2.5. Intramuscular Route

3.6. Value Propositions of Thermostable Vaccines
3.7. Future Perspectives

4. MARKET LANDSCAPE: THERMOSTABLE VACCINES AND BIOLOGICS
4.1. Chapter Overview
4.2. Thermostable Vaccines and Biologics: Product Pipeline
4.2.1. Analysis by Type of Biologics
4.2.2. Analysis by Type of Formulation
4.2.3. Analysis by Type of Manufacturing Technologies
4.2.4. Analysis by Trial Phase
4.2.5. Analysis by Route of Administration
4.2.6. Analysis by Type of Storage Condition
4.2.7. Analysis by Disease Indication
4.2.8. Analysis by Therapeutic Area

4.3. Thermostable Vaccines and Biologics: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Leading Developers: Analysis by Number of Products

5. THERMOSTABLE VACCINES AND BIOLOGICS MANUFACTURERS IN NORTH AMERICA
5.1. Chapter Overview
5.2. Allena Pharmaceuticals
5.2.1. Company Overview
5.2.2. Allena Pharmaceutical: Thermostable Product Portfolio
5.2.3. Recent Developments and Future Outlook

5.3. Amarillo Biosciences
5.3.1. Company Overview
5.3.2. Amarillo Biosciences: Thermostable Product Portfolio

5.4.  Vaxart
5.4.1. Company Overview
5.4.3. Vaxart: Thermostable Product Portfolio
5.4.4. Recent Developments and Future Outlook

6. THERMOSTABLE VACCINES AND BIOLOGICS MANUFACTURERS IN EUROPE
6.1. Chapter Overview
6.2. Tiziana Life Sciences
6.2.1. Company Overview
6.2.2. Tiziana Life Sciences: Thermostable Product Portfolio

6.3. Diabetology (a subsidiary of Proxima Concepts)
6.3.1. Company Overview
6.3.2. Diabetology (a subsidiary of Proxima Concepts): Thermostable Product Portfolio

7. THERMOSTABLE VACCINES AND BIOLOGICS MANUFACTURERS IN ASIA PACIFIC
7.1  Chapter Overview
7.2. Biocon
7.2.1. Company Overview
7.2.2. Biocon: Product Portfolio
7.2.3. Recent Developments and Future Outlook

7.3. Serum Institute of India
7.3.1. Company Overview
7.3.2. Serum Institute of India: Product Portfolio
7.3.3. Recent Developments and Future Outlook

8. COMPANY COMPETITIVENESS ANALYSIS
8.1. Chapter Overview
8.2. Methodology
8.3. Assumptions / Key Parameters
8.4. Competitiveness Analysis: Thermostable Vaccines Service Providers
8.4.1. Competitiveness Analysis: Companies offering Thermostable vaccines in North America
8.4.2. Competitiveness Analysis: Companies offering Thermostable vaccines in Europe
8.4.3. Competitiveness Analysis: Companies offering Thermostable vaccines in Asia Pacific

9. PUBLICATION ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Thermostable Vaccines and Biologics: Publication Analysis
9.3.1. Analysis by Publication Year
9.3.2. Analysis by Type of Publication
9.3.3. Analysis by Focus Area (Therapeutic Area)
9.3.4. ANALYSIS BY IMPACT FACTOR
9.3.5. MOST POPULAR AUTHORS: ANALYSIS BY NUMBER OF PUBLICATIONS
9.3.6. MOST POPULAR JOURNALS: ANALYSIS BY NUMBER OF PUBLICATIONS

10. PARTNERSHIPS AND COLLABORATIONS
10.1. CHAPTER OVERVIEW
10.2. PARTNERSHIP MODELS
10.3. THERMOSTABLE VACCINES AND BIOLOGICS: PARTNERSHIPS AND COLLABORATIONS
10.3.1. ANALYSIS BY YEAR OF PARTNERSHIP
10.3.2. ANALYSIS BY TYPE OF PARTNERSHIP
10.3.3. ANALYSIS BY TYPE AND YEAR OF PARTNERSHIP
10.3.4. ANALYSIS BY TYPE OF PARTNER
10.3.5. ANALYSIS BY YEAR OF PARTNERSHIP AND TYPE OF PARTNER
10.3.6. MOST ACTIVE PLAYERS: ANALYSIS BY NUMBER OF PARTNERSHIPS

10.3.7. GEOGRAPHICAL ANALYSIS
10.3.7.1. ANALYSIS BY INTRACONTINENTAL AND INTERCONTINENTAL AGREEMENT

11. FUNDING AND INVESTMENT ANALYSIS
11.1. CHAPTER OVERVIEW
11.2. TYPES OF FUNDING INSTANCES 
11.3. THERMOSTABLE VACCINES AND BIOLOGICS: RECENT FUNDING INSTANCES
11.3.1. ANALYSIS BY YEAR OF INVESTMENT
11.3.2. ANALYSIS BY AMOUNT INVESTED
11.3.3. ANALYSIS BY TYPE OF FUNDING
11.3.4. MOST ACTIVE PLAYERS: ANALYSIS BY NUMBER OF FUNDING INSTANCES
11.3.5 MOST ACTIVE INVESTORS: ANALYSIS BY NUMBER OF FUNDING INSTANCES
11.4. CONCLUDING REMARKS

12. MARKET SIZING AND OPPORTUNITY ANALYSIS
12.1. CHAPTER OVERVIEW
12.2. SCOPE AND LIMITATIONS
12.3. KEY ASSUMPTIONS AND FORECAST METHODOLOGY
12.4. OVERALL THERMOSTABLE VACCINES AND BIOLOGICS MARKET, 2021-2035
12.5. THERMOSTABLE VACCINES AND BIOLOGICS MARKET, 2021-2035: DISTRIBUTION BY TYPE OF MOLECULE
12.6. THERMOSTABLE VACCINES AND BIOLOGICS MARKET, 2021-2035: DISTRIBUTION BY TYPE OF INDICATION
12.7. THERMOSTABLE VACCINES AND BIOLOGICS MARKET, 2021-2035: DISTRIBUTION BY THERAPEUTIC AREA
12.8. THERMOSTABLE VACCINES AND BIOLOGICS MARKET, 2021-2035: DISTRIBUTION BY KEY PLAYERS
12.8. THERMOSTABLE VACCINES AND BIOLOGICS MARKET, 2021-2035: DISTRIBUTION BY GEOGRAPHICAL REGION
12.9. PRODUCT-WISE SALES FORECAST
12.9.1. ROTASIIL (SERUM INSTITUTE OF INDIA)
12.9.1.1. TARGET PATIENT POPULATION
12.9.1.2. SALES FORECAST (USD MILLION)

12.9.2. VXA-A1.1(VAXART)
12.9.2.1. TARGET PATIENT POPULATION
12.9.2.2. SALES FORECAST (USD MILLION)

12.9.3. VXA-NVV-105 (VAXART)
12.9.3.1. TARGET PATIENT POPULATION
12.9.3.2. SALES FORECAST (USD MILLION)

12.9.4. RELAXOLIASE (ALLENA PHARMACEUTICALS)
12.9.4.1. TARGET PATIENT POPULATION
12.9.4.2. SALES FORECAST (USD MILLION)

13. CONCLUSION
13.1. CHAPTER OVERVIEW

14. EXECUTIVE INSIGHTS

15. APPENDIX 1: TABULATED DATA

16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Executive Summary: Current Market Landscape of Thermostable Vaccines and Biologics
Figure 2.2 Executive Summary: Publication Analysis
Figure 2.3 Executive Summary: Partnership and Collaboration Analysis
Figure 2.4 Executive Summary: Funding Analysis
Figure 2.5 Executive Summary: Market Forecast and Opportunity Analysis
Figure 3.1 Classification of Conventional Vaccines
Figure 4.1 Thermostable Vaccines and Biologics: Distribution by Type of Molecule
Figure 4.2 Thermostable Vaccines and Biologics: Distribution by Storage Conditions
Figure 4.3 Thermostable Vaccines and Biologics: Distribution by Type of Manufacturing Technologies
Figure 4.4 Thermostable Vaccines and Biologics: Distribution by Trial Phase
Figure 4.5 Thermostable Vaccines and Biologics: Distribution by Route of Administration
Figure 4.6 Thermostable Vaccines and Biologics: Distribution by Type of Indication
Figure 4.7 Thermostable Vaccines and Biologics: Distribution by Type of Therapeutic Area
Figure 4.8 Thermostable Vaccines and Biologics Developers: Distribution by Year of Establishment
Figure 4.9 Thermostable Vaccines and Biologics Developers: Distribution by Company Size
Figure 4.10 Thermostable Vaccines and Biologics Developers: Distribution by Location of Headquarters
Figure 4.11 Leading Developers: Distribution by Number of Products
Figure 8.1 Thermostable Vaccines and Biologics: Distribution by Company Competitiveness
Figure 8.2 Thermostable Vaccines and Biologics: Distribution in North America
Figure 8.3 Thermostable Vaccines and Biologics: Distribution in Europe
Figure 8.4 Thermostable Vaccines and Biologics: Distribution in Asia Pacific
Figure 9.1 Thermostable Vaccines and Biologics: Distribution by Year of Publication Thermostable Vaccines and Biologics
Figure 9.2 Thermostable Vaccines and Biologics: Distribution by Most Popular Author
Figure 9.3 Thermostable Vaccines and Biologics: Distribution by Distribution by Impact Factor
Figure 9.4 Thermostable Vaccines and Biologics: Distribution by Most Popular Journal
Figure 9.5 Thermostable Vaccines and Biologics: Distribution by Therapeutic Area
Figure 10.1 Thermostable Vaccines and Biologics: Distribution by Year of Partnership
Figure 10.2 Thermostable Vaccines and Biologics: Distribution by Type of Partnership
Figure 10.3 Thermostable Vaccines and Biologics: Distribution by Year and Type of Partnership
Figure 10.4 Thermostable Vaccines and Biologics: Distribution by Type of Partner
Figure 10.5 Thermostable Vaccines and Biologics: Distribution by Location of Headquarters
Figures 10.6 Thermostable Vaccines and Biologics: Distribution by Intracontinental and Intercontinental Agreements
Figure 10.7 Leading Developers: Distribution by Number of Partnership
Figures 10.8 Thermostable Vaccines and Biologics: World Map presentation based on Number of Partnership
Figure 11.1 Thermostable Vaccine and Biologics: Distribution by Year of Investment
Figure 11.2 Thermostable Vaccine and Biologics: Distribution by Amount Invested
Figure 11.3 Thermostable Vaccine and Biologics: Distribution by Type of Funding
Figure 11.4 Leading Developers: Based on Number of Funding Instances
Figure 12.1 Figure 10.1 Global Thermostable Vaccines and Biologics Market, 2021-2035 (USD Million)
Figure 12.2 Thermostable Vaccines and Biologics Market, 2021-2035: Distribution by Type of Therapy (USD Million)
Figure 12.3 Thermostable Vaccines and Biologics Market, 2021-2035: Distribution by Therapeutic Approach (USD Million)
Figure 12.4 Thermostable Vaccines and Biologics Market, 2021-2035: Distribution by Therapeutic Area (USD Million)
Figure 12.5 Thermostable Vaccines and Biologics Market, 2021-2035: Distribution by Geographical Region (USD Million)
Figure 12.6 Rotasiil Target Patient Population (Till 2035)
Figure 12.7 Rotasiil Sales Forecast (Till 2035): Base Scenario (USD Million)
Figure 12.8 VXA-A1.1 Target Patient Population (Till 2035)
Figure 12.9 VXA-A1.1 Sales Forecast (Till 2035): Base Scenario (USD Million)
Figure 12.10 VXA-NVV-105 Target Patient Population (Till 2035)
Figure 12.11 VXA-NVV-105 Sales Forecast (Till 2035): Base Scenario (USD Million)
Figure 12.12 Relaxoliase Target Patient Population (Till 2035)
Figure 12.13 Relaxoliase Sales Forecast (Till 2035): Base Scenario (USD Million)
Figure 13.1 Concluding Remarks: Current Market Landscape
Figure 13.2 Concluding Remarks: Company Competitiveness Analysis
Figure 13.3 Concluding Remarks: Publication Analysis
Figure 13.4 Concluding Remarks: Recent Partnerships
Figure 13.5 Concluding Remarks: Funding Analysis
Figure 13.6 Concluding Remarks: Market Sizing and Opportunity Analysis

List Of Tables

Table 3.1 Thermostable Vaccines and Biologics: Classification Based on Method of Development.
Table 3.2 Thermostable Vaccines and Biologics: List of Conventional Vaccines Stable at Room Temperature
Table 4.1 Thermostable Vaccines and Biologics: Information on Type of Molecule, Route of Administration, Type of formulation, Technology, Phase of Development, Storage Condition, Indication and Therapeutic Area.
Table 4.2 Thermostable Vaccines and Biologics Developers: Information of Year of Establishment, Company Size and Location of Headquarters
Table 4.3 Thermostable Vaccines and Biologics: List of Technologies and Developers
Table 5.1 Thermostable Vaccines and Biologics: List of Manufacturers in North America
Table 5.2 Allena Pharmaceuticals: Company Snapshot
Table 5.3 Allena Pharmaceuticals: Product Portfolio
Table 5.4 Allena Pharmaceuticals: Recent Developments and Future Outlook
Table 5.5 Amarillo Biosciences: Company Snapshot
Table 5.6 Amarillo Biosciences: Product Portfolio
Table 5.7 Vaxart: Company Snapshot
Table 5.8 Vaxart: Product Portfolio (VXA-A1.1)
Table 5.9 Vaxart: Product Portfolio (VXA.G1.1-NN)
Table 5.10 Vaxart: Recent Developments and Future Outlook
Table 6.1 Thermostable Vaccines and Biologics: List of Manufacturers in Europe
Table 6.2 Diabeteology: Company Snapshot
Table 6.3 Diabeteology: Product Portfolio (Capsulin™ IR)
Table 6.4 Diabeteology: Product Portfolio (Capsulin™ OAD)
Table 6.5 Tiziana Life Sciences: Company Snapshot
Table 6.6 Tiziana Life Sciences: Product Portfolio
Table 7.1 Thermostable Vaccines and Biologics: List of Manufacturers in Asia Pacific
Table 7.2 Biocon: Company Snapshot
Table 7.3 Biocon: Product Portfolio
Table 7.4 Biocon: Recent Developments and Future Outlook
Table 7.5 Serum Institute of India: Company Snapshot
Table 7.6 Serum Institute of India: Product Portfolio
Table 7.7 Serum Institute of India: Recent Developments and Future Outlook
Table 8.1 Thermostable Vaccines and Biologics: Information on Title of Publication, Type of study, Year of Publication, Focus Area, Target Therapeutic Area, Type of Journal and PubMed ID
Table 10.1 Thermostable Vaccines and Biologics: List of Partnerships and Collaborations, 2015-2021(till September)
Table 11.1 Thermostable Vaccines and Biologics: List of Funding Instances. 2015-2021 (till September)
Table 12.1 Thermostable Vaccines and Biologics: Expected Launch Years of Advanced Stage Candidates

List Of Companies

The following companies and organizations have been mentioned in the report. 

  1. Acorn Biomedical
  2. Aegis Therapies 
  3. Affilogic
  4. Allena Pharmaceuticals
  5. Altimmune
  6. Amarillo Biosciences
  7. Aphios
  8. Arecor
  9. Assembly Biosciences
  10. Avaxia Biologics
  11. Batavia Biosciences
  12. Biocon
  13. BioLingus
  14. Chiasma Pharma
  15. Cosmo Pharmaceuticals
  16. Creative Biolabs
  17. CureVac
  18. Diabetology 
  19. Diasome Pharmaceuticals
  20. Elarex
  21. Enesi Pharma
  22. enGene
  23. Entera Bio
  24. Entrega
  25. Enteris BioPharma
  26. Esperovax
  27. Evonik
  28. Gattefosse
  29. Generex Biotechnology
  30. Iconovo
  31. ImmunityBio
  32. Immuron
  33. Innovate UK
  34. Intrexon
  35. Inventprise
  36. iosBio
  37. Jordanian Pharmaceutical Manufacturing
  38. Jurata Thin Film
  39. Latch Medical
  40. Longevity Biotech
  41. Micron Biomedical (Micron)
  42. MidaSol Therapeutics
  43. Midatech Pharma
  44. MigVax
  45. Mynvax
  46. NanoMega Medical
  47. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  48. Niagara University
  49. Nova Laboratories
  50. Nutrinia
  51. Oramed Pharmaceuticals
  52. Oravax Medical
  53. Prokarium
  54. Protagonist Therapeutics
  55. Proxima Concepts
  56. PvP Biologics
  57. QuadMedicine
  58. Rani Therapeutics
  59. Rapid Dose Therapeutics (RDT)
  60. Serum Institute of India
  61. Sigmoid Pharma
  62. Soligenix
  63. StoneStable
  64. Swansea University
  65. Synergy Pharmaceuticals
  66. Tamarix Technologies Group
  67. TFF Pharmaceuticals
  68. Tiziana Life Sciences
  69. Transgene Biotek
  70. Universal Stabilization Technologies (UST)
  71. University of Montreal
  72. Vaxart
  73. Vaxess Technologies
  74. Vaxxas
  75. VBI Vaccines
  76. Verndari 
  77. VHsquared
  78. ViroVet Livestock Solutions
  79. VitriVax
  80. XBiotech
  81. Ziccum

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com

This site uses cookies for better browsing experienceAccept

Copyright © 2023 Roots Analysis. All Rights Reserved.